Mustang Bio (MBIO) Announces $12.8M Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma – StreetInsider.com
|
Mustang Bio (MBIO) Announces $12.8M Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
StreetInsider.com Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech, Inc. (NASDAQ: FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today … |
